Protocol

CNS1123: Phase II Trial of Response-Based Radiation Therapy for Patients With Localized Central Nervous System Germ Cell Tumors

Diseases

Brain Tumor : Newly diagnosed localize primary NGGCT or newly diagnosed localized germinoma

Description

A germinoma germ cell tumor can be malignant (cancerous) and can sometimes spread though the brain and spinal canal before symptoms appear. There are different types of germ cell tumors. Doctors find out which type a person has based on the results of a biopsy and/or tumor markers. A biopsy is a surgical procedure that removes a portion of the tumor for testing. Tumor markers are found by testing for chemical substances (such as proteins) that are produced by tumor cells and released into the body fluids.

Non-germinomatous germ cell tumor (NGGCT) is a type of brain cancer. This tumor is sometimes localized. The term localized means that the tumor has not spread to other parts of the brain or the body. A NGGCT can be malignant (cancerous) and can sometimes spread through the brain and the spinal canal before symptoms appear.


Objectives


Eligibility Criteria, among others, include:


Contact

Ibrahim Qaddoumi, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
901-595-2544 or 901-595-4599
FAX: 901-595-5353

Or

Tabatha E. Doyle, RN
Coordinator, Brain Tumor Program
Phone: 901-595-2544

For the current eligibility status of this clinical study, patient’s family, relatives and/or referring physicians may contact St. Jude Children’s Research Hospital at (901) 595-4599 or (901) 595-2544.

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.